 This study will be conducted using a double-blind, placebo-controlled, randomized, multicenter design to investigate the impact of omalizumab on Quality of Life QoL in Chronic Spontaneous Urticaria CSU and will assess its effectiveness in reducing andor inhibiting the occurrence, time-course and severity of angioedema episodes. 